EP Patent

EP0875245A2 — Substained release polymer blend matrix for pharmaceutical application

Assigned to Hercules LLC · Expires 1998-11-04 · 28y expired

What this patent protects

A pharmaceutical composition has a blend of at least first and second components and a medicament in a sufficient amount to be therapeutic where the first component is selected from hydroxypropylcellulose (HPC), ethylcellulose (EC), or derivatives of HPC, EC and hydroxyethylcellu…

USPTO Abstract

A pharmaceutical composition has a blend of at least first and second components and a medicament in a sufficient amount to be therapeutic where the first component is selected from hydroxypropylcellulose (HPC), ethylcellulose (EC), or derivatives of HPC, EC and hydroxyethylcellulose (HEC) and the second component is at least one polymer. When HPC is the first component, hydroxypropylmethyl-cellulose (HMC), HEC or carboxymethylcellulose will not be the second component and when EC is the first component, HPMC will not be the second component. The medicament can be a variety of drugs or nutritional supplements. The pharmaceutical composition releases the medicament for a prolonged or sustained period of time and can be formulated into many dosage forms.

Drugs covered by this patent

Patent Metadata

Patent number
EP0875245A2
Jurisdiction
EP
Classification
Expires
1998-11-04
Drug substance claim
No
Drug product claim
No
Assignee
Hercules LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.